Aleglitazar No Help Against Coronary Events

March 31, 2014 9:25 PM

25 0

Aleglitazar No Help Against Coronary Events

WASHINGTON -- Treatment with the investigative diabetes drug aleglitazar lowered blood glucose levels in diabetes patients but did not improve cardiovascular outcomes, researchers said here.

In calculating the impact on the composite endpoint of cardiovascular death, heart attack, or stroke, Michael Lincoff, MD, director of the Cleveland Clinic Coordinating Center for Clinical Research, said 9.5% of patients over the 3-year course of the study experienced the endpoint compared with 10% ...

Read more

To category page